Main Subject - Finance

There is a wide spectrum of timeframes in which one can invest, from buy and hold for 3 years or more, to a medium term investment lasting 6-9 months, to a 3-month short term investment and all the way down to a week long swing trade or plain intraday trading. Most buy and hold investors re

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

alise that the return they have earned is not the best for the period they have invested in it, considering price movement has not been uniformly directional but has had numerous interim corrections, which could have enabled them to earn a lot more if they had called more of these interim c

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

rrections correctly. Ideally, they would have like to reverse their position during the interim corrections or at least exit the trade and invest the cash in a savings account or money market fund during the correction. On the other extreme, most day traders – who try to catch every turn in

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

the market every hour seem to lose money. So if this be the case, there ought to be some point in between where your investment performance could be optimised. What exactly is that time frame? Or in other words what is the optimal trading frequency? But even more critically, should you att

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

empt to optimise your trading frequency? and how should you do it?

The first step in answering these questions is to understand the economics of trading at the points of reversal. Every time a trader exits a position because of an anticipated trend reversal or takes an opposing stance, he

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

bviously incurs costs. These costs can be split into structural costs and analysis costs. Structural costs include brokerage, bid-ask spread (which arises due to illiquidity) and slippage costs which the trader incurs when he cannot get the exact price in fast moving markets. The analysis c

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

sts can be broken down into trend identification costs and whipsaws. Unless one was using highly accurate reversal prediction tools (I am not aware of any), a trader would almost always have to wait for some confirmation of reversal by allowing the price to move in the reversed direction fo

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

r some time. This can be termed as trend identification cost. Even after delaying action to await confirmation of trend reversal, traders are faced with the possibility of a whipsaw or false confirmation of trend reversal. Traders who got out of a long term trend to play a shorter term corr

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ction do many times run the risk of missing out on the main long term trend should their assessment of the correction go awry and the stock actually make a big move in the direction of their original position. The return a trader makes during periods of corrections, either by taking a oppos

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

te stance or by investing in money markets, should exceed these transaction costs. So the trade-off is between the return earned during the time period for which stock undergoes correction and the transaction costs.

In his book “Channels and Cycles: A tribute to J M Hurst”, noted technical

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

analyst and author Brian Millard examines the trading frequency issue by studying the 5 year performance of the 30-Dow constituents between 1993 and 1998. Assuming a 5% transaction and illiquidity costs, and assuming that an investor typically enters or exits the trade a few days after the

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

actual trend has begun (the trend identification cost is measured as time delay rather than adverse price in this case), Millard concludes that the optimum trading length should be between 50 and 100 trading days.

Millard’s assessment is over ten years old. We have had substantial changes

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

in the markets with the rise (and subsequent crash) of Nasdaq, rapid growth in hedge fund industry and increased individual participation in markets through online trading. With these, I would expect some significant change in Millard’s finding. Also, over the last five years, we have been

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

itnessing a steady and steep decline in brokerage costs. By choosing fairly liquid securities with low bid-ask spreads the transaction costs can be brought down substantially. All of these probably would make it meaningful to trade short corrective swings, if one could call the turns correc

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

tly. I would have expected the optimum trading length to have come down, to something like 30 to 60 trading days. I am sure one can run a similar study now, based on different input parameters to come out with a more refined assessment but I believe under all combinations of input parameter

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

, there does exist an optimum trading length somewhere between that of the swing trader and the buy and hold investor.

I certainly believe both, the very short term traders and very long term investors would benefit by attempting a minor change in their trading frequency while broadly stic

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ing with their original trading style. The short term trader has to make a conscious attempt at avoiding the excessive transaction costs while the long term investor would be better off anticipating corrections.

Fundamental analysis is never a tool to identify corrections. Playing the corr

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

ections requires reasonably fairly accurate timing which fundamental analysis does not promise to identify for you. If you invest solely based on fundamentals, I would recommend that you stick to a buy and hold approach and not attempt to play the corrections. However, technical Analysis ca

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

be very effectively used to anticipate trend reversals both in terms of timing and price levels. Adding technical tools to your arsenal can be of immense help.

Similarly, pure technical traders would benefit significantly from getting a fundamental understanding of the stocks that they tr

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

de in. A technical trader taking a particular directional position is likely to stick to his original trade even in the wake of a temporary whipsaw, and avoid the stop loss switch, in case he had a certain level of comfort in the immediate fundamentals (or the trend of the next higher order

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.mainsubjects.org.ua/article/89493/mainsubjects-Should-You-Optimise-Your-Trading-Frequency.html">Should You Optimise Your Trading Frequency</a>

BB link (for phorums):
[url=http://www.mainsubjects.org.ua/article/89493/mainsubjects-Should-You-Optimise-Your-Trading-Frequency.html]Should You Optimise Your Trading Frequency[/url]

Have you ever gone to have your Business Cards printed especially using internet printing companies but have walked away baffled, confused and disappointed with the jargon and the printed product.

This article outlines seven essential steps to setting up a successful performance improvement initiative

A newsletter is one of the best marketing tools to keep in constant conact with your prospects and customers. It helps to position you as expert in your field, attracts new business, and it can be a stepping stone to speaking invitations at events that can result in new business.

Tags

Links

Main Subject - Should You Optimise Your Trading Frequency

Related Articles: